{"id":951,"date":"2025-09-05T14:16:11","date_gmt":"2025-09-05T14:16:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/951\/"},"modified":"2025-09-05T14:16:11","modified_gmt":"2025-09-05T14:16:11","slug":"rna-therapeutics-market-size-to-reach-usd-26-13-billion-by-2034","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/951\/","title":{"rendered":"RNA Therapeutics Market Size to Reach USD 26.13 Billion by 2034"},"content":{"rendered":"

<\/p>\n

According to Nova One Advisor, the global RNA
\ntherapeutics market size<\/a> is expected to be worth around 26.13 billion
\nby 2034, increasing from USD 8.55 billion in 2025, representing a healthy CAGR
\nof 13.22% from 2025 to 2034.<\/p>\n

<\/p>\n

The RNA therapeutics market is growing as
\nit is a significant tool for the treatment of various types of serious
\ndiseases, particularly genetically mutated diseases such as cancer, metabolic
\ndisorders. With the growing applications of genome sequencing, growing numbers
\nof intronic variants will be recognized by clinical diagnostic testing. RNA
\nanalysis provides insight into the diseases and mechanisms leading to death and
\nhas developed into a valuable technology for the diagnosis of the cause of
\ndeath in forensic science.<\/p>\n

The Complete Study is Now Available for
\nImmediate Access | Download the Sample Pages of this Report@ https:\/\/www.novaoneadvisor.com\/report\/sample\/9205<\/a>\n<\/p>\n

RNA Therapeutics Market Highlights:<\/p>\n

\u2b25\ufe0e North America dominated the RNA
\ntherapeutics market with the largest share in 2024.<\/p>\n

\u2b25\ufe0e Asia Pacific is expected to grow at
\nthe fastest CAGR during the forecast period of 2025 and 2034.<\/p>\n

\u2b25\ufe0e By type, the mRNA therapeutics segment
\nled the market in 2024.<\/p>\n

\u2b25\ufe0e By type, the RNA interference (RNAi)
\ntherapeutics segment is expected to expand at the highest CAGR in the coming
\nyears.<\/p>\n

\u2b25\ufe0e By product, the vaccines segment held
\nthe largest share of the market in 2024.<\/p>\n

\u2b25\ufe0e By product, the drugs segment is
\nlikely to grow at a significant rate over the forecast period.<\/p>\n

\u2b25\ufe0e By indication, the infectious diseases
\nsegment dominated the market in 2024.<\/p>\n

\u2b25\ufe0e By indication, the rare genetic
\ndisorders\/hereditary diseases segment is expected to expand at a rapid pace in
\nthe upcoming period.<\/p>\n

\u2b25\ufe0e By end-user, the hospitals &
\nclinics segment held the largest market share in 2024.<\/p>\n

\u2b25\ufe0e By end-user, the research institutes
\nsegment is expected to grow at the fastest rate during the projection period.<\/p>\n

Market Overview and Industry Potential<\/p>\n

Ribonucleic acid (RNA<\/a>)-based
\ntherapies are an emergent area of therapeutic development that provides the
\nstrength to produce novel treatments for a wide range of conditions. These
\ntherapeutics are utilized to characterize mRNA expression profiles in different
\ntissues and progress assays for particular mRNA molecules in forensic contexts.\n<\/p>\n

RNA
\nsequencing<\/a> has become a model technology in modern biology and clinical
\nscience. Its enormous popularity is due in large part to the incessant efforts
\nof the bioinformatics community to progress precise and scalable computational technologies
\nto analyze the massive amounts of transcriptomic data that it produces.<\/p>\n

RNA research has gathered noteworthy
\nattention due to its profound consequences in drug development and therapeutic
\ndiscovery. Advanced research in RNA biology integrated with progress in
\ndelivery technologies holds the promise of renovating RNA-based therapeutics
\ninto conventional clinical practice. RNA-Seq identifies differentially
\nexpressed transcripts and reveals novel molecular mechanisms of disease.<\/p>\n

Approved RNA Therapies as of Q3 2024<\/p>\n

Product Name<\/p>\n

Generic Name<\/p>\n

Year
\n First\u00a0Approved<\/p>\n

Disease(s)<\/p>\n

Locations Approved<\/p>\n

Originator Company<\/p>\n

CSPC Pharmaceutical\u00a0COVID-19 vaccine<\/p>\n

COVID-19 vaccine, CSPC\u00a0Pharmaceutical<\/p>\n

2023<\/p>\n

Infection, coronavirus, novel
\n coronavirus prophylaxis<\/p>\n

China<\/p>\n

CSPC Pharmaceutical<\/p>\n

Sinocelltech COVID-19\u00a0vaccine<\/p>\n

COVID-19\u00a0alpha\/beta\/delta\/Omicron\u00a0variants
\n S-trimer quadrivalent\u00a0recombinant protein vaccine<\/p>\n

2023<\/p>\n

Infection, coronavirus, novel
\n coronavirus prophylaxis<\/p>\n

China, UAE, U.S.<\/p>\n

Sinocelltech<\/p>\n

Izervay<\/p>\n

avacincaptad pegol sodium<\/p>\n

2023<\/p>\n

Wet age-related macular
\n degeneration<\/p>\n

U.S.<\/p>\n

Archemix<\/p>\n

Qalsody<\/p>\n

tofersen<\/p>\n

2023<\/p>\n

Amyotrophic lateral sclerosis<\/p>\n

U.S., EU<\/p>\n

Ionis Pharmaceuticals<\/p>\n

ARCT-154<\/p>\n

COVID-19 mRNA vaccine, Arcturus<\/p>\n

2023<\/p>\n

Infection, coronavirus, novel
\n coronavirus prophylaxis<\/p>\n

Japan<\/p>\n

Arcturus Therapeutics<\/p>\n

Daichirona<\/p>\n

COVID-19 vaccine, Daiichi Sankyo<\/p>\n

2023<\/p>\n

Infection, coronavirus, novel
\n coronavirus prophylaxis J<\/p>\n

Japan<\/p>\n

Daiichi Sankyo<\/p>\n

Wainua<\/p>\n

eplontersen<\/p>\n

2023<\/p>\n

Transthyretin-related hereditary
\n amyloidosis<\/p>\n

U.S., Canada<\/p>\n

Ionis Pharmaceuticals<\/p>\n

Rivfloza<\/p>\n

nedosiran<\/p>\n

2023<\/p>\n

Hyperoxaluria<\/p>\n

U.S.<\/p>\n

Dicerna Pharmaceuticals<\/p>\n

SYS-6006.32<\/p>\n

Bivalent COVID-19 mRNA
\n vaccine,\u00a0CSPC Pharmaceutical<\/p>\n

2023<\/p>\n

Infection, coronavirus, novel coronavirus
\n prophylaxis<\/p>\n

China<\/p>\n

CSPC Pharmaceutical<\/p>\n

RQ-3033<\/p>\n

COVID-19 mRNA vaccine,
\n Walvax\u00a0Biotechnology<\/p>\n

2023<\/p>\n

Infection, coronavirus, novel
\n coronavirus prophylaxis<\/p>\n

China<\/p>\n

Walvax Biotechnology<\/p>\n

Rytelo<\/p>\n

imetelstat<\/p>\n

2024<\/p>\n

Myelodysplastic syndrome<\/p>\n

U.S.<\/p>\n

Geron<\/p>\n

mRESVIA<\/p>\n

respiratory syncytial virus
\n vaccine,\u00a0Moderna
\n Therapeutics<\/p>\n

2024<\/p>\n

Respiratory syncytial virus
\n prophylaxis<\/p>\n

U.S., EU<\/p>\n

Moderna Therapeutics<\/p>\n

Latest Trends of the Market<\/p>\n

\u2714
\nIn August 2025, Alnylam
\nPharmaceuticals, Inc<\/a>., the leading RNAi therapeutics company, announced
\nthat the Company will present new data from its hypertension and transthyretin
\namyloidosis (ATTR) programs at the upcoming European Society of Cardiology
\n(ESC) Congress<\/p>\n

\u2714
\nIn May 2025, Biogen Inc. and City Therapeutics, Inc., a
\nprivately held biopharmaceutical company leading the future of RNA interference
\n(RNAi)-based medicine, announced a strategic collaboration to develop select
\nnovel RNAi therapies. Through the collaboration, City Therapeutics will
\nleverage its next-generation RNAi engineering technologies to develop an RNAi
\ntrigger molecule combined with proprietary drug delivery technology from
\nBiogen.<\/p>\n

Recent Advancements in RNA Sequencing:
\nMarket\u2019s Largest Potential<\/p>\n

Recent developments in high-throughput RNA
\nsequencing<\/a>, single-cell RNA sequencing, and epitranscriptomics further
\nunravelled the complexity of RNA biology, shedding light on the details of gene
\nregulation and the diversity of cells. The incorporation of computational
\ndevices and bioinformatics has driven the identification of RNA-driven
\nbiomarkers and the development of RNA
\ntherapeutics<\/a>. <\/p>\n

\u2b25\ufe0e For Instance, In June 2025, BioNTech
\nSE and CureVac N.V. announced that they had entered into a definitive Purchase
\nAgreement pursuant to which BioNTech intended to acquire all of the shares of
\nCureVac, a clinical-stage biotech company developing a novel class of
\ntransformative medicines in oncology and infectious diseases based on messenger
\nribonucleic acid.<\/p>\n

Buy Now Full Report: https:\/\/www.novaoneadvisor.com\/report\/checkout\/9205<\/a>\n<\/p>\n

Report Scope of RNA Therapeutics Market<\/p>\n

Report Coverage<\/p>\n

Details<\/p>\n

Market Size in 2025<\/p>\n

USD 8.55 Billion<\/p>\n

Market Size by 2034<\/p>\n

USD 26.13 Billion<\/p>\n

Growth Rate From 2025 to 2034<\/p>\n

CAGR of 13.22%<\/p>\n

Base Year<\/p>\n

2024<\/p>\n

Forecast Period<\/p>\n

2025-2034<\/p>\n

Segments Covered<\/p>\n

By Type, By Product, By Indication, By
\n End-User, By Region<\/p>\n

Market Analysis (Terms Used)<\/p>\n

Value (US$ Million\/Billion) or
\n (Volume\/Units)<\/p>\n

Regional scope<\/p>\n

North America; Europe; Asia Pacific;
\n Latin America; MEA<\/p>\n

RNA Therapeutics Market Segmentation
\nAnalysis:<\/p>\n

By Type Analysis:<\/p>\n

The mRNA
\ntherapeutics<\/a> segment dominated in the RNA therapeutics market, as it is
\nused for a variety of diseases that are resistant to present treatments, like
\nmetabolic genetic diseases, infectious diseases, cancer, cardiovascular
\ndisease, cerebrovascular diseases, and others. mRNA-based therapeutics are
\ncharacterized by their fast advancement and manufacturing capability. mRNA
\ntechnology permits the quick testing of hundreds of potential vaccine targets.<\/p>\n

On the other hand, the RNA interference
\n(RNAi) therapeutics segment is expected to grow significantly during the
\nforecast period, as it can target potentially any gene in the genome, containing
\ntargets that are undruggable by small molecules and antibodies. They have more
\npotent and durable effects. It is administered by multiple routes, intravenous
\n(IV), subcutaneous, and intrathecal delivery. <\/p>\n

By Product Analysis:<\/p>\n

The vaccines<\/a>
\nsegment dominated the market in 2024, as it has high efficiency in preventing
\nserious diseases. The significant advantages of mRNA
\nvaccines<\/a> are their higher success rate in preventing severe
\nhospitalization, illness, and death. RNA vaccines have benefits in safety,
\nefficacy, affordability, speed, and simplicity of production.<\/p>\n

On the other hand, the drugs segment is
\nexpected to grow at the fastest CAGR in the market during the forecast period,
\nas RNA-based drugs are a quickly expanding category of drugs based on RNA
\nmolecules goal of treating or preventing diseases. <\/p>\n

By Indication Analysis:<\/p>\n

The infectious
\ndiseases segment<\/a> dominated the market in 2024, as mRNA vaccines have
\nthe potential for the fastest response to large-scale outbreaks of infectious
\ndiseases, like COVID-19. It has always been the researchers’ intention to
\nenhance the stability, translation efficiency, immunogenicity, and delivery
\nsystem to achieve effective and harmless delivery of mRNA for treating
\ninfectious diseases.<\/p>\n

On the other hand, the rare genetic
\ndisorders\/hereditary diseases segment is expected to grow at the fastest CAGR
\nin the market during the forecast period, as mRNA therapies for rare genetic
\ndiseases, like protection against degradation and immune clearance, organ
\ntargeting, and lowering intracellular immunotoxicity, along with delivery
\nvehicles and mRNA modifications for efficient expression and lifespan. mRNA
\ntreatments to address the large unmet requirement in rare genetic disorders.<\/p>\n

By End User Analysis:<\/p>\n

The hospitals and clinics segment dominated
\nthe market in 2024, as their strength to target undruggable targets that
\ntraditional therapeutics cannot. RNA therapeutics, predominantly ASOs and
\nsiRNAs, bind to their target through sequence\u2010specific
\nbinding. Novel RNA therapeutics are rapidly developed and produced using
\ncurrent modification processes and delivery technologies.<\/p>\n

On the other hand, the research institutes
\nsegment is expected to grow at the fastest CAGR in the market during the
\nforecast period, as RNA-based therapies show a promising and fast advancing
\nsector in medicine. The unique characteristics of RNA, its ability to regulate
\ngene expression, its flexibility in targeting specific genes, and its potential
\nfor targeted medicine have created the opportunity for the development of novel
\ntreatments. RNA-driven therapeutics hold huge potential for managing a broad
\nrange of diseases, including infectious diseases, cancer, and genetic
\ndisorders.<\/p>\n

Regional Insights<\/p>\n

North America led the RNA therapeutics
\nmarket in 2024, as the growing prevalence of chronic and rare disease
\nconditions, combined with a vital requirement for precision medicine, is
\ndriving investments and progress in the RNA solution space. Increasing
\ninvestments in RNA science, increasing awareness of genetic disorders, and the
\nsuccessful deployment of mRNA-based vaccines.<\/p>\n

\u2b25\ufe0e For Instance, In September 2025,
\nIllumina Inc. announced the launch of Illumina Protein Prep, an assay
\nintroducing superior performance for next-generation sequencing (NGS) based
\nproteomics discovery at scale. Illumina Protein Prep has been available through
\nan early-access program and is broadly available to customers worldwide,
\nenabling researchers to add proteomics to large-scale genomics studies and
\ndrive new insights across cancer and cardio metabolic, and immunologic
\ndiseases, with a streamlined sample-to-insights solution for discovery and
\nclinical research.<\/p>\n

In the U.S., noteworthy government and
\nprivate spending in research and development, an advanced biotechnology sector,
\nand presence skilled workforce, helpful regulatory pathways from the US FDA,
\nthe potential to manage genetic disorders, and development in delivery systems,
\ndriving the growth of the market.<\/p>\n

Why is Asia Pacific the Fastest Growing
\nin the RNA Therapeutics Market?<\/p>\n

APAC is fastest fastest-growing region in
\nthe market, with revolutionary technological advancements, growing healthcare
\napplications, and a speedily growing pipeline of novel therapeutics. Recent
\ndevelopments in RNA delivery, modification, and manufacturing are driving wider
\nacceptance and commercialization, enhancing the precision of RNA treatments and
\ncreating opportunities for targeted medicine and gene therapies.<\/p>\n

Buy Now Full Report: https:\/\/www.novaoneadvisor.com\/report\/checkout\/9205<\/a>\n<\/p>\n

Region-Wise Growth Overview of the RNA
\nTherapeutics Market:<\/p>\n

Region<\/p>\n

Market Size (2024)<\/p>\n

Projected CAGR (2025-2034)<\/p>\n

Key Growth Drives<\/p>\n

Key Challenges<\/p>\n

Market Outlook<\/p>\n

North America<\/p>\n

USD\u00a03.1\u00a0Bn<\/p>\n

~6.65%<\/p>\n

Advanced R&D capabilities, robust
\n biotech infrastructure, strong funding support<\/p>\n

High development costs, stringent
\n regulatory requirements<\/p>\n

Dominant and steadily growing market<\/p>\n

Asia Pacific<\/p>\n

USD\u00a02.2\u00a0Bn<\/p>\n

~7.89%<\/p>\n

Rising healthcare investments, large
\n patient base, supportive government policies<\/p>\n

Infrastructure gaps, price sensitivity in
\n some markets<\/p>\n

Fastest-growing and rapidly emerging
\n region<\/p>\n

Europe<\/p>\n

USD\u00a01.8\u00a0Bn<\/p>\n

~10.76%<\/p>\n

Healthcare innovation, collaborative
\n R&D, regulatory facilitation (e.g., EMA)<\/p>\n

Slow regulatory pathways, reimbursement
\n constraints<\/p>\n

Stable growth<\/p>\n

Latin America<\/p>\n

USD\u00a00.6\u00a0Bn<\/p>\n

~5.24%<\/p>\n

Expanding healthcare infrastructure,
\n growing demand for advanced therapies<\/p>\n

Limited funding, regulatory complexity<\/p>\n

Emerging market with strong growth
\n potential<\/p>\n

MEA<\/p>\n

USD\u00a00.4\u00a0Bn<\/p>\n

~4.14%<\/p>\n

Government-backed healthcare projects,
\n increasing biotech interest<\/p>\n

Infrastructure deficiencies, skilled
\n workforce shortages<\/p>\n

Underpenetrated but promising growth<\/p>\n

RNA Therapeutics Market Companies:<\/p>\n

\u2022 ISIS Pharmaceuticals<\/p>\n

\u2022 Quark Pharmaceuticals<\/p>\n

\u2022 Alnylam Pharmaceuticals<\/p>\n

\u2022 Dice a Pharmaceuticals<\/p>\n

\u2022 Tekmira Pharmaceuticals Corp.<\/p>\n

\u2022 Benitec Biopharma Limited<\/p>\n

\u2022 Genzyme Corporation<\/p>\n

\u2022 Silence Therapeutics PLC<\/p>\n

\u2022 Cenix BioScience GmbH<\/p>\n

What is Going Around the Globe?<\/p>\n

\u2b25\ufe0e In March 2025, Alnylam
\nPharmaceuticals, Inc., the leading RNAi therapeutics company, highlighted the
\nsignificance of the U.S. Food and Drug Administration\u2019s approval of Qfitlia,
\nthe sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first
\nand only therapeutic to lower antithrombin (AT), a protein that inhibits blood
\nclotting, to promote thrombin generation to rebalance hemostasis and prevent
\nbleeds.<\/p>\n

\u2b25\ufe0e In June 2025, Lexeo Therapeutics,
\nInc., a clinical-stage genetic medicine company dedicated to pioneering novel
\ntreatments for cardiovascular diseases, announced a strategic partnership to
\ndevelop therapies for genetic cardiac diseases utilizing a novel non-viral RNA
\nplatform. Combined with investment of up to $40 million from leading life-sciences
\ninvestors Perceptive Xontogeny Venture Funds and venBio Partners, the
\npartnership seeks to further revolutionize the treatment of cardiovascular
\ndiseases.<\/p>\n

\u2b25\ufe0e In January 2025, Inverna Therapeutics,
\na novel Danish biotech company at the forefront of innovative RNA therapeutics,
\nannounced its launch as a leading-edge RNA therapeutics company.\u00a0 The Company
\nwas co-founded by the University of Southern Denmark and Argobio and is
\ndedicated to transforming patient outcomes in severe genetic diseases, starting
\nwith a lead program addressing Huntington\u2019s disease.<\/p>\n

You can place an order or ask any
\nquestions, please feel free to contact at\u00a0sales@novaoneadvisor.com<\/a> \u00a0|
\n+1 804 441 9344<\/p>\n

Related Report<\/p>\n

\u2b25\ufe0e mRNA Therapeutics Market – https:\/\/www.precedenceresearch.com\/mrna-therapeutics-market<\/a>\n<\/p>\n

\u2b25\ufe0e U.S. mRNA Therapeutics Market – https:\/\/www.precedenceresearch.com\/us-mrna-therapeutics-market<\/a>\n<\/p>\n

\u2b25\ufe0e Next-Generation RNA Therapeutics Market – https:\/\/www.precedenceresearch.com\/next-generation-rna-therapeutics-market<\/a>\n<\/p>\n

\u2b25\ufe0e mRNA Therapeutics CDMO Market – https:\/\/www.precedenceresearch.com\/mrna-therapeutics-cdmo-market<\/a>\n<\/p>\n

Segments Covered in the Report<\/p>\n

This report forecasts revenue growth at
\ncountry levels and provides an analysis of the latest industry trends in each
\nof the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc.
\nhas segmented the RNA therapeutics market.<\/p>\n

By Type<\/p>\n

\u2022 RNA Interference (RNAi) Therapeutics<\/p>\n

\u2022 mRNA Therapeutics<\/p>\n

\u2022 Antisense Oligonucleotide (ASO)
\nTherapeutics<\/p>\n

\u2022 Others<\/p>\n

By Product<\/p>\n

\u2022 Vaccines<\/p>\n

\u2022 Drugs<\/p>\n

By Indication<\/p>\n

\u2022 Rare Genetic Disorders\/Hereditary
\nDiseases<\/p>\n

\u2022 Infectious Diseases<\/p>\n

\u2022 Others (Metabolic Disorders, Auto-immune
\nDisorders, and Oncology)<\/p>\n

By End-User<\/p>\n

\u2022 Research Institutes<\/p>\n

\u2022 Hospitals & Clinics<\/p>\n

By Regional<\/p>\n

\u2022 North America<\/p>\n

\u2022 Europe<\/p>\n

\u2022 Asia Pacific<\/p>\n

\u2022 Latin America<\/p>\n

\u2022 Middle East and Africa (MEA)<\/p>\n

Immediate Delivery Available | Buy This
\nPremium Research https:\/\/www.novaoneadvisor.com\/report\/checkout\/9205<\/a>\n<\/p>\n

About-Us<\/p>\n

Nova One Advisor is a global leader
\nin market intelligence and strategic consulting, committed to delivering deep,
\ndata-driven insights that power innovation and transformation across
\nindustries. With a sharp focus on the evolving landscape of life sciences, we
\nspecialize in navigating the complexities of cell and gene therapy, drug
\ndevelopment, and the oncology market, enabling our clients to lead in some of
\nthe most revolutionary and high-impact areas of healthcare.<\/p>\n

Our expertise spans the entire
\nbiotech and pharmaceutical value chain, empowering startups, global
\nenterprises, investors, and research institutions that are pioneering the next
\ngeneration of therapies in regenerative medicine, oncology, and precision
\nmedicine. <\/p>\n

Web: https:\/\/www.novaoneadvisor.com\/<\/a><\/p>\n

Contact Us<\/p>\n

USA:\u00a0+1 804 420 9370<\/p>\n

Email: sales@novaoneadvisor.com<\/a><\/p>\n

For Latest Update Follow Us: LinkedIn<\/a> <\/p>\n

\u00a0<\/p>\n<\/p><\/p>\n","protected":false},"excerpt":{"rendered":"According to Nova One Advisor, the global RNA therapeutics market size is expected to be worth around 26.13…\n","protected":false},"author":2,"featured_media":952,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[72,61,60,123],"class_list":{"0":"post-951","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-ie","10":"tag-ireland","11":"tag-markets"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=951"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/951\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/952"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}